221 related articles for article (PubMed ID: 28273349)
1. A radiobiological model of reoxygenation and fractionation effects.
Guerrero M; Carlson DJ
Med Phys; 2017 May; 44(5):2002-2010. PubMed ID: 28273349
[TBL] [Abstract][Full Text] [Related]
2. Theoretical effectiveness of cell survival in fractionated radiotherapy with hypoxia-targeted dose escalation.
Chvetsov AV; Rajendran JG; Zeng J; Patel SA; Bowen SR; Kim EY
Med Phys; 2017 May; 44(5):1975-1982. PubMed ID: 28236652
[TBL] [Abstract][Full Text] [Related]
3. A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC).
Strigari L; Benassi M; Sarnelli A; Polico R; D'Andrea M
Med Phys; 2012 Jul; 39(7):4502-14. PubMed ID: 22830782
[TBL] [Abstract][Full Text] [Related]
4. Optimal fractionation in radiotherapy for non-small cell lung cancer--a modelling approach.
Lindblom E; Dasu A; Toma-Dasu I
Acta Oncol; 2015; 54(9):1592-8. PubMed ID: 26217986
[TBL] [Abstract][Full Text] [Related]
5. Effect of reoxygenation on hypofractionated radiotherapy of prostate cancer.
Kuperman VY; Lubich LM
Med Phys; 2020 Oct; 47(10):5383-5391. PubMed ID: 32583529
[TBL] [Abstract][Full Text] [Related]
6. Impact of SBRT fractionation in hypoxia dose painting - Accounting for heterogeneous and dynamic tumor oxygenation.
Kjellsson Lindblom E; Ureba A; Dasu A; Wersäll P; Even AJG; van Elmpt W; Lambin P; Toma-Dasu I
Med Phys; 2019 May; 46(5):2512-2521. PubMed ID: 30924937
[TBL] [Abstract][Full Text] [Related]
7. Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
Shibamoto Y; Miyakawa A; Otsuka S; Iwata H
J Radiat Res; 2016 Aug; 57 Suppl 1(Suppl 1):i76-i82. PubMed ID: 27006380
[TBL] [Abstract][Full Text] [Related]
8. Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?
Santiago A; Barczyk S; Jelen U; Engenhart-Cabillic R; Wittig A
Radiat Oncol; 2016 May; 11():67. PubMed ID: 27154064
[TBL] [Abstract][Full Text] [Related]
9. Optimal dose and fraction number in SBRT of lung tumours: A radiobiological analysis.
Ruggieri R; Stavrev P; Naccarato S; Stavreva N; Alongi F; Nahum AE
Phys Med; 2017 Dec; 44():188-195. PubMed ID: 28130055
[TBL] [Abstract][Full Text] [Related]
10. Computed 88% TCP dose for SBRT of NSCLC from tumour hypoxia modelling.
Ruggieri R; Stavreva N; Naccarato S; Stavrev P
Phys Med Biol; 2013 Jul; 58(13):4611-20. PubMed ID: 23771131
[TBL] [Abstract][Full Text] [Related]
11. A novel dose-volume metric for optimizing therapeutic ratio through fractionation: retrospective analysis of lung cancer treatments.
Keller H; Hope A; Meier G; Davison M
Med Phys; 2013 Aug; 40(8):084101. PubMed ID: 23927363
[TBL] [Abstract][Full Text] [Related]
12. A simple mathematical model of cyclic hypoxia and its impact on hypofractionated radiotherapy.
Taylor E
Med Phys; 2023 Mar; 50(3):1893-1904. PubMed ID: 36594511
[TBL] [Abstract][Full Text] [Related]
13. Revisiting the formalism of equivalent uniform dose based on the linear-quadratic and universal survival curve models in high-dose stereotactic body radiotherapy.
Chan MKH; Chiang CL
Strahlenther Onkol; 2021 Jul; 197(7):622-632. PubMed ID: 33245378
[TBL] [Abstract][Full Text] [Related]
14. Critical dose and toxicity index of organs at risk in radiotherapy: analyzing the calculated effects of modified dose fractionation in non-small cell lung cancer.
Pedicini P; Strigari L; Benassi M; Caivano R; Fiorentino A; Nappi A; Salvatore M; Storto G
Med Dosim; 2014; 39(1):23-30. PubMed ID: 24239409
[TBL] [Abstract][Full Text] [Related]
15. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy.
Park C; Papiez L; Zhang S; Story M; Timmerman RD
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):847-52. PubMed ID: 18262098
[TBL] [Abstract][Full Text] [Related]
16. Monte Carlo radiotherapy simulations of accelerated repopulation and reoxygenation for hypoxic head and neck cancer.
Harriss-Phillips WM; Bezak E; Yeoh EK
Br J Radiol; 2011 Oct; 84(1006):903-18. PubMed ID: 21933980
[TBL] [Abstract][Full Text] [Related]
17. Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.
Liang X; Penagaricano J; Zheng D; Morrill S; Zhang X; Corry P; Griffin RJ; Han EY; Hardee M; Ratanatharathom V
Radiat Oncol; 2016 Jan; 11():10. PubMed ID: 26800883
[TBL] [Abstract][Full Text] [Related]
18. Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer.
Huang BT; Lin Z; Lin PX; Lu JY; Chen CZ
Oncotarget; 2016 Jun; 7(26):40746-40755. PubMed ID: 27203739
[TBL] [Abstract][Full Text] [Related]
19. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
20. Modeling of the resensitization effect on carbon-ion radiotherapy for stage I non-small cell lung cancer.
Inaniwa T; Kanematsu N; Nakajima M
Phys Med Biol; 2024 May; 69(10):. PubMed ID: 38604184
[No Abstract] [Full Text] [Related]
[Next] [New Search]
